HRGN · Harvard Apparatus Regenerative Technology, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Because these resources are not expected to fund the Company's operations for at least 12 months from the date the financial statements are issued, substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $982K | $704K | $430K | $103K | — | $0 | $0 | $0 | $0 | $0 | $82K | $118K | $93K | $22K | $0 | |
| $908K | $646K | $270K | $24K | — | — | — | — | — | $0 | $116K | $139K | $48K | $11K | $0 | |
| — | — | — | — | — | — | — | — | — | $0 | -$34K | -$21K | $45K | $11K | $0 | |
| — | — | — | — | — | — | — | — | — | — | -41.46% | -17.8% | 48.39% | 50% | — | |
| $2.87M | $2.65M | $2.31M | $3.06M | $1.74M | $1.59M | $2.07M | $4.85M | $3.92M | $7.59M | $7.6M | $4.79M | $5.12M | $4.56M | $4.03M | |
| $449K | — | $554K | $294K | — | — | — | — | — | — | — | $289K | $329K | $259K | $116K | |
| $3.83M | $4.25M | $5.02M | $5.71M | $4.41M | — | — | — | — | — | — | $6.61M | $5.65M | $4.01M | $2.57M | |
| $4.92M | — | — | — | $4.41M | $7.04M | $3.26M | $4.02M | $3.93M | $3.88M | $4.49M | $6.89M | — | — | — | |
| $8.42M | — | — | $9.09M | $6.15M | $8.64M | $5.33M | $8.87M | $7.84M | $11.47M | $12.09M | $11.68M | $11.1M | $8.83M | $6.71M | |
| $7.69M | $7.62M | $8.16M | $9.09M | — | — | — | — | — | — | — | — | — | — | — | |
| -$6.71M | -$6.92M | -$7.73M | -$8.99M | -$6.15M | -$8.64M | -$5.33M | -$8.87M | -$7.84M | -$11.47M | -$12.13M | -$11.7M | -$11.06M | -$8.82M | -$6.71M | |
| — | -982.24% | -1796.74% | -8728.16% | — | — | — | — | — | — | -14787.8% | -9916.1% | -11889.25% | -40077.27% | — | |
| $13K | $8000 | $38K | $14K | $9000 | — | — | — | — | — | — | — | — | — | — | |
| $19K | $37K | $32K | $64K | — | — | — | — | — | — | — | — | — | — | — | |
| $27K | $46K | -$6000 | $45K | $80K | $658K | $460K | $538K | $312K | -$448K | $547K | -$3000 | -$4000 | $0 | — | |
| — | -$6.87M | -$7.73M | — | — | — | — | — | — | -$11.92M | -$11.58M | -$11.7M | -$11.06M | -$8.82M | -$6.71M | |
| — | $0 | $0 | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$6.68M | -$6.87M | -$7.73M | -$8.95M | -$6.07M | -$7.98M | -$4.87M | -$8.33M | -$7.53M | -$11.92M | -$11.58M | -$11.7M | -$11.06M | -$8.82M | -$6.71M | |
| — | -975.71% | -1798.14% | -8684.47% | — | — | — | — | — | — | -14120.73% | -9918.64% | -11893.55% | -40077.27% | — | |
| — | — | -$7.73M | -$9.02M | -$6.25M | -$7.98M | — | — | — | — | — | — | — | — | — | |
| -$6.68M | -$6.88M | -$7.74M | -$8.95M | — | — | — | — | — | -$11.92M | -$11.57M | -$11.71M | -$11.06M | -$8.82M | — | |
| USD/shares | — | -$0.42 | -$0.52 | -$0.67 | -$0.55 | -$0.79 | -$0.55 | — | — | — | — | — | — | — | — |
| USD/shares | — | — | — | -$0.67 | -$0.55 | -$0.79 | -$0.55 | — | — | — | — | — | — | — | — |
| shares | — | 16.52M | 14.79M | 13.46M | 11.35M | 10.06M | 8.79M | 6.9M | 4.46M | 1.8M | 799K | 11.15M | 7.82M | 7.74M | 7.74M |
| shares | — | — | — | 13.46M | 11.35M | 10.06M | 8.79M | 6.9M | 4.46M | 1.8M | 799K | 11.15M | 7.82M | 7.74M | 7.74M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2021: $42K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 31 similar-size Packaged Foods companies (of 74 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Consumer Health Products | $704,000 | $430,000 | $103,000 |
| Regenerative Biotech | $0 | $0 | $0 |